Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes

New England Journal of Medicine(2022)10.1056/nejmoa2200433Source: DataRank Database

Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes is a research paper published in New England Journal of Medicine (2022). On theSindex it has a DataRank of 5.4. It has been cited 213 times, with 100 citing works in its 1-hop citation network.

N/A

5.4DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access213 citations · 100 citing works in its network

Free full text

Cite:

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT01794143

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (30 grants)Impact (FWCI 24.95)OA: bronzeTopics (46)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 15%Citation Network 85%

Base Score Contribution

0.805

From this paper's citation signal

Citation Network Contribution

4.6

From 100 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 100 citers.

After Metformin — Next Steps for Type 2 Diabetes with Low Cardiovascular Risk
New England Journal of Medicine20228 citations9 referencesContributes 0.244
Glycemia Reduction in Type 2 Diabetes — Microvascular and Cardiovascular Outcomes
New England Journal of Medicine2022156 citations26 referencesContributes 0.194
Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
BMJ2023280 citations44 referencesContributes 0.128
Approach to the Patient With Type 2 Diabetes Requiring Add-On Medication
The Journal of Clinical Endocrinology & Metabolism202413 citations21 referencesContributes 0.126
Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial
Diabetes Care202479 citations35 referencesContributes 0.125

Authors (1)

The GRADE Study Research Group

Live enrichment

PubMed:36129996 OpenAlex:https://openalex.org/W4296702771

National Institute of Diabetes and Digestive and Kidney Diseases

Grant: U01DK098246

National Institute of Diabetes and Digestive and Kidney Diseases

Grant: U34DK088043

NIDDK NIH HHS

Grant: U01 DK119083

NCATS NIH HHS

Grant: UL1 TR000445

NCATS NIH HHS

Grant: UL1 TR002529

NCATS NIH HHS

Grant: UL1 TR002541

NIDDK NIH HHS

Grant: P30 DK111022

NCATS NIH HHS

Grant: UL1 TR000439

NIDDK NIH HHS

Grant: P30 DK020541

NCATS NIH HHS

Grant: UL1 TR002378

NCATS NIH HHS

Grant: UL1 TR001425

NIDDK NIH HHS

Grant: P30 DK020572

NCATS NIH HHS

Grant: UL1 TR002243

NCATS NIH HHS

Grant: UL1 TR002345

NIDDK NIH HHS

Grant: P30 DK017047

NCATS NIH HHS

Grant: UL1 TR002548

NCATS NIH HHS

Grant: UL1 TR002537

NIDDK NIH HHS

Grant: P30 DK092926

NCATS NIH HHS

Grant: UL1 TR002535

NIDDK NIH HHS

Grant: P30 DK072476

NIDDK NIH HHS

Grant: P30 DK079626

NCATS NIH HHS

Grant: UL1 TR001409

NCATS NIH HHS

Grant: UL1 TR001449

NCATS NIH HHS

Grant: UL1 TR002489

NIGMS NIH HHS

Grant: U54 GM104940

NCATS NIH HHS

Grant: UL1 TR001108

NCATS NIH HHS

Grant: UL1 TR000170

NCATS NIH HHS

Grant: UL1 TR002556

NCATS NIH HHS

Grant: UL1 TR001102

NIDDK NIH HHS

Grant: P30 DK124723

FWCI

24.95

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

bronzeLicense: http://www.nejmgroup.org/legal/terms-of-use.htm

journalhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa2200433?articleTools=true

publisherhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa2200433?articleTools=true

publisherhttp://www.nejm.org/doi/pdf/10.1056/NEJMoa2200433

journalhttps://doi.org/10.1056/nejmoa2200433

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36129996

Fields of Study

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and ResearchBlood GlucoseComparative Effectiveness ResearchDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsDrug Therapy, CombinationGlucagon-Like Peptide-1 ReceptorGlycated HemoglobinHumansHypoglycemic AgentsInsulin GlargineLiraglutideMetforminSitagliptin PhosphateSulfonylurea CompoundsTreatment OutcomeGlucagon-Like Peptide-1 Receptor Agonists

MeSH Terms

Glucagon-Like Peptide-1 ReceptorSitagliptin PhosphateInsulin GlargineLiraglutideGlucagon-Like Peptide-1 Receptor AgonistsBlood GlucoseDiabetes Mellitus, Type 2Drug Therapy, CombinationGlycated HemoglobinHumansHypoglycemic AgentsMetforminSulfonylurea CompoundsTreatment OutcomeDipeptidyl-Peptidase IV InhibitorsComparative Effectiveness Research

Keywords

Glycated hemoglobinMetforminType 2 diabetesGlycemicMedicineDiabetes mellitusInternal medicineGlycemic indexGlycated haemoglobinIntensive care medicineEndocrinology

Sustainable Development Goals

SDG 0: Zero hunger